Guía de práctica clínica: tamizaje, diagnóstico y manejo de episodios agudos y profilaxis del angioedema hereditario Parte I: Enfoque diagnóstico / Clinical practice guidelines: screening, diagnosis and management of acute events and prophylaxis of hereditary angioedema Part I: Diagnostic approach
Arq. Asma, Alerg. Imunol
; 4(4): 382-393, out.dez.2020. ilus
Article
in Spanish
| LILACS
| ID: biblio-1382033
Responsible library:
BR2717.9
RESUMEN
El angioedema hereditario (AEH) es una enfermedad genética rara, con una prevalencia aproximada entre 1 por cada 50.000 habitantes, caracterizada por episodios de edemas a nivel subcutáneo y de mucosas (abdominal, genitourinario, respiratoria), siendo potencialmente mortal cuando hay afectación de la laringe. En Perú se estiman 600 pacientes con AEH. El AEH se puede clasificar del siguiente modo con deficiencia del inhibidor de C1 (tipos I y II), y sin deficiencia del inhibidor de C1 (denominado anteriormente tipo III). El diagnóstico de laboratorio incluye prueba de complemento C4, prueba cuantitativa y cualitativa para inhibidor de C1 esterasa, y estudios genéticos.
ABSTRACT
Hereditary angioedema (HAE) is a genetic rare disease with a prevalence of approximately 1 per 50,000 inhabitants, characterized by episodes of edema at the subcutaneous level and mucous membranes (abdominal, genitourinary, respiratory), being potentially fatal when there is involvement of the larynx. In Peru, there are an estimated 600 patients with HAE. HAE can be classified as follows with C1 inhibitor deficiency (types I and II), and without C1 inhibitor deficiency (previously called type III). Laboratory diagnosis includes C4 complement test, quantitative and qualitative tests for C1 inhibitor esterase, and genetic studies. In this first part of the Clinical Practice Guide, we present the recommendations for the diagnostic approach of HAE.
Full text:
Available
Collection:
International databases
Health context:
SDG3 - Health and Well-Being
/
SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases
Health problem:
Target 3.4: Reduce premature mortality due to noncommunicable diseases
/
Cardiovascular Disease
/
Skin Diseases
Database:
LILACS
Main subject:
Peru
/
Mass Screening
/
Clinical Laboratory Techniques
/
Diagnosis
/
Angioedemas, Hereditary
Type of study:
Diagnostic study
/
Practice guideline
/
Qualitative research
/
Risk factors
/
Screening study
Limits:
Humans
Country/Region as subject:
South America
/
Peru
Language:
Spanish
Journal:
Arq. Asma, Alerg. Imunol
Journal subject:
Biologia
/
Cincia
Year:
2020
Document type:
Article
Affiliation country:
Peru
Institution/Affiliation country:
Essalud - Sede Central/PE
/
Hospital Nacional Arzobispo Loayza/PE
/
Hospital Nacional Guillermo Almenara Irigoyen/PE
/
Hospital Nacional Hipólito Unánue MINSA/PE
/
Sociedad Peruana de Alergia, Asma e Inmunología/PE
/
TSI-LEAN SALUD/PE